Meta-analysis of relapse prevention antidepressant trials in depressive disorders

The Australian and New Zealand Journal of Psychiatry
Paul GlueBirol Emir

Abstract

Continuation therapy with antidepressants is recommended for depressed patients who have responded to initial treatment. We quantified its efficacy in preventing relapse of depression in a meta-analysis of 54 double-blind placebo-controlled relapse prevention studies (patient n = 9268). Relapse prevention studies in primary depression and depression subtypes were identified in a systematic literature search. The primary efficacy comparison was relapse rates between active and placebo arms calculated as odds ratios (ORs) using Review Manager version 5.0. Effects of patient age, drug class, diagnostic system and duration of therapy on ORs was examined, along with ORs calculated using different statistical methods. Continuation antidepressants produced robust reduction in relapse (OR = 0.35; 95%CI 0.32-0.39). Pooled ORs were not affected by patient age, drug class, depression subtype or treatment duration, and were similar when calculated by different statistical methods. Patients with primary depression diagnosed by earlier diagnostic systems had slightly lower ORs than those diagnosed using DSM criteria. This meta-analysis emphasizes the importance of continuation treatment following acute response in depressive disorders. The r...Continue Reading

References

Jul 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·A CoppenA Jorgensen
Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Feb 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·D P Doogan, V Caillard
Jun 11, 1990·Journal of Clinical Psychopharmacology·S W JenkinsL A Reich
Jan 1, 1991·Psychopharmacology·R K SchwartingJ P Huston
Dec 1, 1990·Archives of General Psychiatry·E FrankV J Grochocinski
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jan 1, 1984·Neuropsychobiology·J Davidson, D Raft
Mar 1, 1982·The American Journal of Psychiatry·D BialosL Harkness
Mar 1, 1995·International Clinical Psychopharmacology·P Robert, S A Montgomery
Jan 1, 1994·Acta Psychiatrica Scandinavica·A KishimotoN Kunimoto
Jan 1, 1993·International Clinical Psychopharmacology·S A MontgomeryP Tanghøj
Sep 1, 1996·Archives of General Psychiatry·J H KocsisM Parides
Jul 1, 1997·International Clinical Psychopharmacology·M FerreriJ M Leger
Jul 21, 1998·International Clinical Psychopharmacology·J L Terra, S A Montgomery
Dec 1, 1998·JAMA : the Journal of the American Medical Association·M B KellerW Harrison
Jul 13, 1999·The Journal of Clinical Psychiatry·M VersianiR Arnaud-Castiglioni
Mar 11, 2000·Archives of General Psychiatry·G S AlexopoulosJ Hull
May 10, 2000·Journal of Affective Disorders·F RouillonJ Chwalow
Apr 3, 2001·The British Journal of Psychiatry : the Journal of Mental Science·B HochstrasserR Nil
Jul 31, 2001·Journal of Clinical Psychopharmacology·I GilaberteUNKNOWN Fluoxetine Long-Term Study Group
Jan 31, 2002·The Journal of Clinical Psychiatry·M E ThaseUNKNOWN Relapse Prevention Study Group
Apr 10, 2002·JAMA : the Journal of the American Medical Association·B Timothy WalshMadelyn Gould
Jul 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·René KlysnerHans Erik Høpfner Petersen
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Arif KhanEarl L Giller
Jun 5, 2003·The British Journal of Psychiatry : the Journal of Mental Science·K C M WilsonM T Abou-Saleh
Jul 16, 2003·Archives of General Psychiatry·Dennis S CharneyUNKNOWN Depression and Bipolar Support Alliance
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Jan 28, 2004·The Journal of Clinical Psychiatry·Mark Hyman RapaportHongjie Zheng
Mar 9, 2004·Journal of Psychiatric Research·Jeffrey S SimonDean Lei
Mar 9, 2004·Journal of Psychiatric Research·Jay D AmsterdamMichael Gibertini
Apr 21, 2004·The Journal of Clinical Psychiatry·Stuart A MontgomeryUNKNOWN Venlafaxine 335 Study Group

❮ Previous
Next ❯

Citations

Feb 16, 2012·British Medical Bulletin·Eleni Palazidou
Nov 3, 2011·The Australian and New Zealand Journal of Psychiatry·Paul B Fitzgerald
Jul 15, 2015·The International Journal of Neuropsychopharmacology·Kang SimRoss J Baldessarini
Oct 28, 2016·Psychological Medicine·I M BerwianQ J M Huys
Jul 26, 2017·Contemporary Clinical Trials·Daniel J Safer
May 15, 2018·Psychotherapy and Psychosomatics·Christien SlofstraClaudi L H Bockting
May 21, 2019·The Cochrane Database of Systematic Reviews·Katja MachmutowSarah Liebherz
Nov 30, 2019·Psychological Medicine·Johan OrmelSteven D Hollon
Feb 9, 2017·Translational Psychiatry·W-C ChiuP-C Chen
Oct 13, 2017·The International Journal of Neuropsychopharmacology·Oloruntoba J OlubokaPierre Blier
Apr 10, 2019·BMJ : British Medical Journal·Parashar RamanujHarold Alan Pincus
Jun 27, 2018·Archives of Women's Mental Health·C J PopeD Mazmanian
Dec 11, 2020·Neuropsychiatric Disease and Treatment·Gang WangChee H Ng
Apr 23, 2021·The Cochrane Database of Systematic Reviews·Ellen Van LeeuwenThierry Christiaens
Sep 30, 2021·The New England Journal of Medicine·Gemma LewisGlyn Lewis
Nov 30, 2021·Health Technology Assessment : HTA·Larisa DuffyGlyn Lewis

❮ Previous
Next ❯

Software Mentioned

Comprehensive Analysis
R
Review Manager
SAS
Cochran

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.